Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12094-014-1268-5 http://scihub22266oqcxt.onion/10.1007/s12094-014-1268-5 C4448077!4448077!25617146     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Transl+Oncol 2015 ; 17 (6): 419-30 Nephropedia Template TP {{tp|p=25617146|t=2015. Giant cell tumour of bone: new treatments in development |pdf=|usr=}}{{25617146}} gab.com Text Giant cell tumour of bone: new treatments in development JO: Clin Transl Oncol http://www.kidney.de/pget.php?&tw=1&pmid=25617146 #FOAvip Giant cell tumour of bone (GCTB) is a benign osteolytic tumour with three main cellular components: multinucleated osteoclast-like giant cells, mononuclear spindle-like stromal cells (the main neoplastic components) and mononuclear cells of the monocyte/macrophage lineage. The giant cells overexpress a key mediator in osteoclastogenesis: the RANK receptor, which is stimulated in turn by the cytokine RANKL, which is secreted by the stromal cells. The RANK/RANKL interaction is predominantly responsible for the extensive bone resorption by the tumour. Historically, standard treatment was substantial surgical resection, with or without adjuvant therapy, with recurrence rates of 20?56 %. Studies with denosumab, a monoclonal antibody that specifically binds to RANKL, resulted in dramatic treatment responses, which led to its approval by the United States Food and Drugs Administration (US FDA). Recent advances in the understanding of GCTB pathogenesis are essential to develop new treatments for this locally destructive primary bone tumour. Twit Text FOAVip Giant cell tumour of bone: new treatments in development ????Clin Transl Oncol http://www.kidney.de/pget.php?&tw=1&pmid=25617146 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25617146 #FOAvip English Wikipedia <ref>{{Cite pmid|25617146}}</ref> Giant cell tumour of bone: new treatments in development #MMPMID25617146 López-Pousa A; Broto JM; Garrido T; Vázquez J Clin Transl Oncol 2015[]; 17 (6): 419-30 PMID25617146show ga Giant cell tumour of bone (GCTB) is a benign osteolytic tumour with three main cellular components: multinucleated osteoclast-like giant cells, mononuclear spindle-like stromal cells (the main neoplastic components) and mononuclear cells of the monocyte/macrophage lineage. The giant cells overexpress a key mediator in osteoclastogenesis: the RANK receptor, which is stimulated in turn by the cytokine RANKL, which is secreted by the stromal cells. The RANK/RANKL interaction is predominantly responsible for the extensive bone resorption by the tumour. Historically, standard treatment was substantial surgical resection, with or without adjuvant therapy, with recurrence rates of 20?56 %. Studies with denosumab, a monoclonal antibody that specifically binds to RANKL, resulted in dramatic treatment responses, which led to its approval by the United States Food and Drugs Administration (US FDA). Recent advances in the understanding of GCTB pathogenesis are essential to develop new treatments for this locally destructive primary bone tumour. äGiant cell tumour of bone: new treatments in development (epmc).pdf DeepDyve Pubget Overpricing